SCHEMBL3007233

SCHEMBL3007233

O=S(=O)(c1cc(C(F)(F)F)ccc1Cl)N1CCN(c2nc(Cc3cc(F)cc(F)c3)cs2)CC1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
ALDH1A1 P00352 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
TSHR P16473 2/20 0.49
ATM Q13315 1/20 0.49
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.40
MAPT P10636 3/20 0.39
LMNA P02545 2/20 0.39
HTR6 P50406 2/20 0.39
GPR6 P46095 1/20 0.38
PKM P14618 2/20 0.38
KDM4E B2RXH2 1/20 0.37
ADRB2 P07550 1/20 0.37
HTT P42858 1/20 0.36
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3002884 0.96 ALDH1A1 (0.47) MEN1KMT2AALDH1A1L3MBTL1TSHR
SCHEMBL3017970 0.92 MEN1 (0.50) MEN1KMT2AALDH1A1L3MBTL1TSHR
SCHEMBL3014399 0.90 MEN1 (0.48) MEN1KMT2AALDH1A1L3MBTL1TSHR
SCHEMBL3012142 0.90 ALDH1A1 (0.48) MEN1KMT2AALDH1A1L3MBTL1TSHR
SCHEMBL3008733 0.90 L3MBTL1 (0.50) MEN1KMT2AALDH1A1L3MBTL1TSHR
SCHEMBL3013015 0.90 RAB9A (0.52) MEN1KMT2AALDH1A1L3MBTL1TSHR
SCHEMBL3010628 0.90 L3MBTL1 (0.50) MEN1KMT2AALDH1A1L3MBTL1TSHR
SCHEMBL3015184 0.89 ALDH1A1 (0.47) MEN1KMT2AALDH1A1L3MBTL1TSHR
SCHEMBL3014834 0.89 ALDH1A1 (0.47) MEN1KMT2AALDH1A1L3MBTL1TSHR
SCHEMBL3010380 0.89 ALDH1A1 (0.44) MEN1KMT2AALDH1A1L3MBTL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MEN1 454/4885KMT2A 2680/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.